WaveMan · Form 4
Enyedy Mark J insider trades
> Search tickers & screens ⌘K
LIVE

Enyedy Mark J insider trades

Enyedy Mark J has filed 18 Form 4s with the SEC that we hold, for IMGN (CHIEF EXECUTIVE OFFICER, Director), Biomarin Pharmaceutical INC (BMRN) (Director), Charles River Laboratories International, INC. (CRL) (Director) and LOGC (Director). Across all of them we count 0 purchases worth $0 and 5 sales worth $51.7M reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a sale of 986,521 shares of IMGN worth $17.2M, dated 2023-08-02. The first filing on our record is dated 2021-07-02 and the latest 2026-06-04.

IMGN

CHIEF EXECUTIVE OFFICER, Director · 10 filings · 5 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-08-02S, sale reported on Form 4986,521$17.2M2023-08-04
2023-08-02S, sale reported on Form 48,636$156.7K2023-08-04
2023-08-03S, sale reported on Form 41,020,000$16.9M2023-08-04
2023-08-04S, sale reported on Form 4992,397$16.8M2023-08-04
2024-02-05S, sale reported on Form 420,107$588.7K2024-02-06

Biomarin Pharmaceutical INC (BMRN)

Director · 4 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Charles River Laboratories International, INC. (CRL)

Director · 2 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

LOGC (LOGC)

Director · 2 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1586965) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms